These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
283 related articles for article (PubMed ID: 37261522)
1. TP53 or CDKN2A/B covariation in ALK/RET/ROS1-rearranged NSCLC is associated with a high TMB, tumor immunosuppressive microenvironment and poor prognosis. Jiang B; Hu L; Dong D; Guo Z; Wei W; Wang C; Shao W; Ma T; Chen Y; Li Q; Hu W J Cancer Res Clin Oncol; 2023 Sep; 149(12):10041-10052. PubMed ID: 37261522 [TBL] [Abstract][Full Text] [Related]
2. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698 [TBL] [Abstract][Full Text] [Related]
3. Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. Zhang B; Zeng J; Zhang H; Zhu S; Wang H; He J; Yang L; Zhou N; Zu L; Xu X; Song Z; Xu S Front Immunol; 2022; 13():974581. PubMed ID: 36159860 [TBL] [Abstract][Full Text] [Related]
4. Clinical relevance of PD-L1 expression and CD8+ T cells infiltration in patients with EGFR-mutated and ALK-rearranged lung cancer. Liu SY; Dong ZY; Wu SP; Xie Z; Yan LX; Li YF; Yan HH; Su J; Yang JJ; Zhou Q; Zhong WZ; Tu HY; Yang XN; Zhang XC; Wu YL Lung Cancer; 2018 Nov; 125():86-92. PubMed ID: 30429043 [TBL] [Abstract][Full Text] [Related]
5. The prognostic role of PD-1, PD-L1, ALK, and ROS1 proteins expression in non-small cell lung carcinoma patients from Egypt. Bahnassy AA; Ismail H; Mohanad M; El-Bastawisy A; Yousef HF J Egypt Natl Canc Inst; 2022 May; 34(1):23. PubMed ID: 35644823 [TBL] [Abstract][Full Text] [Related]
6. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405 [No Abstract] [Full Text] [Related]
7. Clinical significance of TP53 alterations in advanced NSCLC patients treated with EGFR, ALK and ROS1 tyrosine kinase inhibitors: An update. Moes-Sosnowska J; Szpechcinski A; Chorostowska-Wynimko J Tumour Biol; 2024; 46(s1):S309-S325. PubMed ID: 37840519 [TBL] [Abstract][Full Text] [Related]
8. PD-L1 expression in ROS1-rearranged non-small cell lung cancer: A study using simultaneous genotypic screening of EGFR, ALK, and ROS1. Lee J; Park CK; Yoon HK; Sa YJ; Woo IS; Kim HR; Kim SY; Kim TJ Thorac Cancer; 2019 Jan; 10(1):103-110. PubMed ID: 30475455 [TBL] [Abstract][Full Text] [Related]
10. Concomitant TP53 mutations with response to crizotinib treatment in patients with ALK-rearranged non-small-cell lung cancer. Song P; Zhang F; Li Y; Yang G; Li W; Ying J; Gao S Cancer Med; 2019 Apr; 8(4):1551-1557. PubMed ID: 30843662 [TBL] [Abstract][Full Text] [Related]
11. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer. Kron A; Alidousty C; Scheffler M; Merkelbach-Bruse S; Seidel D; Riedel R; Ihle MA; Michels S; Nogova L; Fassunke J; Heydt C; Kron F; Ueckeroth F; Serke M; Krüger S; Grohe C; Koschel D; Benedikter J; Kaminsky B; Schaaf B; Braess J; Sebastian M; Kambartel KO; Thomas R; Zander T; Schultheis AM; Büttner R; Wolf J Ann Oncol; 2018 Oct; 29(10):2068-2075. PubMed ID: 30165392 [TBL] [Abstract][Full Text] [Related]
12. Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective. Aggarwal A; Sharma S; Brar Z; Kumar V; Kumar A; Katara R; Mohanty SK Pathol Res Pract; 2024 Jan; 253():155013. PubMed ID: 38096714 [TBL] [Abstract][Full Text] [Related]
13. Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study. Lu C; Dong XR; Zhao J; Zhang XC; Chen HJ; Zhou Q; Tu HY; Ai XH; Chen XF; An GL; Bai J; Shan JL; Wang YN; Yang SY; Liu X; Zhuang W; Wu HT; Zhu B; Xia XF; Chen RR; Gu DJ; Xu HM; Wu YL; Yang JJ J Hematol Oncol; 2020 Apr; 13(1):37. PubMed ID: 32295619 [TBL] [Abstract][Full Text] [Related]
14. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879 [TBL] [Abstract][Full Text] [Related]
15. Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung Adenocarcinoma. Rangachari D; VanderLaan PA; Shea M; Le X; Huberman MS; Kobayashi SS; Costa DB J Thorac Oncol; 2017 May; 12(5):878-883. PubMed ID: 28104537 [TBL] [Abstract][Full Text] [Related]
16. Programmed death-ligand 1 expression and its associations with clinicopathological features, prognosis, and driver oncogene alterations in surgically resected lung adenocarcinoma. Takamochi K; Hara K; Hayashi T; Kohsaka S; Takahashi F; Suehara Y; Suzuki K Lung Cancer; 2021 Nov; 161():163-170. PubMed ID: 34600407 [TBL] [Abstract][Full Text] [Related]
17. Resistance Mechanisms to Targeted Therapies in McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358 [No Abstract] [Full Text] [Related]
18. Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age. Ke L; Xu M; Jiang X; Sun X Med Sci Monit; 2018 Dec; 24():9364-9369. PubMed ID: 30580372 [TBL] [Abstract][Full Text] [Related]
19. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy. Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients. Song Z; Yu X; Zhang Y Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]